Sucovil 50 mg (Tablet)
Unit Price: ৳ 20.00 (2 x 10: ৳ 400.00)
Strip Price: ৳ 200.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Vildagliptin |
| Company | Globe pharmaceuticals ltd |
Indications
- Improve glycemic control in type 2 diabetes mellitus
- Adjunct to diet and exercise
- Monotherapy
- Dual combination with Metformin
- Dual combination with Sulphonylurea
- Dual combination with Thiazolidinedione
- Dual combination with Insulin
Pharmacology
- Dipeptidyl peptidase-4 (DPP-4) inhibitor
- Slows inactivation of incretin hormones
- Increases insulin release
- Decreases glucagon levels
- Glucose-dependent insulinotropic polypeptide (GIP)
- Glucagon-like peptide-1 (GLP-1)
Dosage & Administration
- Recommended daily dose of 50mg or 100mg for monotherapy
- 50mg twice daily in dual combination with Metformin or Thiazolidinedione
- 50mg once daily in dual combination with a Sulphonylurea
- May be taken with or without a meal
- No dosage adjustment required in elderly or patients with mild renal impairment
- Not recommended in pediatric use (under 18 years of age)
Interaction
- No interactions with pioglitazone, metformin, glibenclamide, digoxin, warfarin, amlodipine, ramipril, valsartan, or simvastatin
- Glucose-lowering effect may be reduced by thiazides, corticosteroids, thyroid products, and sympathomimetics
Contraindications
- Hypersensitivity to active substance or excipients
- Moderate to severe renal impairment
- Hepatic impairment with ALT or AST >3 times the upper limit of normal
- Type 1 diabetes
Side Effects
- Majority of adverse reactions are mild and transient
- Rare case of hepatic dysfunction
- No additional safety signals in trials of up to and more than 2 years duration
Pregnancy & Lactation
- Not to be used in pregnancy
- Not to be used during lactation
Precautions & Warnings
- Caution in patients aged 75 years and older
- LFTs should be monitored prior to initiation and at three-monthly intervals in the first year
- If transaminase levels increased, frequent liver function tests should be conducted
- Discontinue treatment if AST or ALT persists at 3xULN
- Discontinue treatment if jaundice or signs of liver dysfunction develop
- Use with caution in patients with congestive heart failure of NYHA functional class I-II
- Do not use in patients with NYHA functional class III IV
Therapeutic Class
- Dipeptidyl Peptidase-4 (DPP-4) inhibitor
Storage Conditions
- Store below 30°C temperature
- Keep away from light and moisture
- Keep out of reach of children